This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hudis, C. A. Articles by Winer, E. P. Search for Related Content PubMed PubMed Citation Articles by Hudis, C. A. Articles by Winer, E. P.

Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future

Authors' Affiliations: ¹ Memorial Sloan-Kettering Cancer Center, New York, New York and ² Dana-Farber Cancer Institute, Boston, Massachusetts

Requests for reprints: Eric P. Winer, Dana-Farber Cancer Institute, 44 Binney Street, Dana 1210, Boston, MA 02115. Phone: 617-632-6876.

The Breast Committee of the Cancer and Leukemia Group B was formed in 1969 under the direction of James Holland. Initial studies examined combination chemotherapy for advanced disease. Although the committee has continued to conduct studies in patients with advanced disease, adjuvant therapy has been an even more important focus for the past 30 years. Over the past 20 years, studies have focused on optimization of chemotherapy through the testing of dose and schedule, the value of adding novel agents, and the role of biological agents. Current and future projects are aimed at exploiting and increasing our growing knowledge of the molecular biology of breast cancer by developing targeted therapies.